



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 653 154 A2**

EUROPEAN PATENT APPLICATION

Application number: **94117512.7**

Int. Cl.⁶ **A01K 67/027**

Date of filing: **07.11.94**

Priority: **12.11.93 JP 306026/93**

Date of publication of application:
17.05.95 Bulletin 95/20

Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**

Applicant: **HOECHST JAPAN LIMITED**
New Hoechst Building,
10-16 Akasaka 8-chome,
Minato-ku
Tokyo 107 (JP)

Inventor: **Sato, Masahiro**
3-7-10-102 Minamidai
Kawagoe-shi,
Saitama 350-11 (JP)
Inventor: **Kobayashi, Takashi**
7-9-1003 Ohinomachi, Hakata-ku

**Fukuoka-shi,
Fukuoka 812 (JP)**
Inventor: **Tada, Norihiro**
3-7-10-201 Minamidai
Kawagoe-shi,
Saitama 350-11 (JP)
Inventor: **Shoji, Mikio**
599 Kitahara, Gunmachi
Gunma-cho,
Gunma 370-35 (JP)
Inventor: **Kawarabayashi, Takeshi**
1345-19 Aonashicho
Maebashi-shi,
Gunma 371 (JP)

Representative: **Bösl, Raphael Konrad et al**
Hoechst AG
Zentrale Patentabteilung
Gebäude F 821
D-65926 Frankfurt am Main (DE)

Transgenic animal for alzheimer's disease.

This invention relates in general to an animal model that is useful for developing therapeutic drugs of a disease. More in detail, the present invention relates to the creation of transgenic animals having an exogenous gene construct coding a part of β -amyloid precursor protein (hereinafter called APP) in their genome. The exogenous gene construct is designed to overexpress in various types of the cells.




Fig. 1

EP 0 653 154 A2



This invention relates in general to an animal model that is useful for developing therapeutic drugs of a disease. More in detail, the present invention relates to the creation of transgenic animals having an exogenous gene construct coding a part of β -amyloid precursor protein (hereinafter called APP) in their genome. The exogenous gene construct is designed to overexpress in various types of the cells.

Recent development of genetic engineering has made it possible to create embryos (so-called transformed embryos) into which the said gene construct is integrated by microinjection of an exogenous gene construct (DNA) into the nuclei of 1-cell stage embryos or by infection of preimplantation embryos with retroviral vector DNA (Gordon J. et al., *Proc. Natl. Acad. Sci., USA*, Vol. 77, p. 7380-7384, 1980; Jaenisch R. et al., *Cell*, Vol. 32, p. 209-216, 1983). The resulting embryos can further develop to full term after the transfer into the oviducts/uteri of recipient foster mothers. Some of the resulting adult animals have the exogenous DNA integrated into their genome and to express the DNA in its tissues. These "transformed" animals are generally called transgenic animals (Gordon J. and Ruddle F.I. *Science*, Vol. 214, p. 1244-1246, 1981). The integrated exogenous DNA is called transgene, generally consisting of a promoter and a target gene (encoding a protein that is desired to be expressed) and others. The transgene expression can be made even before maturation; for example, in some cases, the expression occurs in the cleavage stage of an embryo. As a result of the expression, a protein produced by the transgene is produced. If the said protein play a crucial role on the morphogenetic pathway of individuals, some phenotypic alteration may occur at a certain stage of development. For giving a phenotypic alteration in transgenic animals, two approaches are possible; 1) overexpression of a target protein in a targeted tissue(s) and 2) suppression of endogenous target gene expression by anti-sense gene technology (Katsuki M. et al., *Science*, Vol. 241, p. 593-595, 1988) and others. These are based upon an usage of tissue-specific or ubiquitous promoter and/or enhancer, both of which should be placed at the upstream target gene.

Up to date, there are many reports to show that transgenic animals exhibited alteration of their original phenotypes due to expression of a transgene. These are mentioned in detail in the reviews by Palmiter R. D. and Brinster R. L. (*Annu. Rev. of Genet.*, Vol. 20, p. 465-499, 1986), Cordon J. W. (*Int. Rev. of Cytobiol.*, Vol. 115, p. 171-229, 1989) and others. These transgenic animals can be utilized in the fields of 1) analysis of gene expression in vivo during embryogenesis, 2) gene therapy for overcoming hereditary genetical diseases, etc. Transformation of an embryo with DNA can be achieved by giving the DNA exogenously; then the added DNA will be integrated into a part of DNA sequence in their chromosomes of the host embryos. For introduction of the exogenous DNA into mammalian embryos, there are several methods. For example, it is widely utilized that DNA is introduced via a micropipett (so-called microinjection method) into the pronuclei of 1-cell stage embryos (Gordon et al., 1980).

By using microinjection method, mammalian embryos into which DNA is injected can develop to full term after transfer to the oviducts or uteri of pseudopregnant female recipients. The delivered living pups can be analyzed later by PCR (polymerase chain reaction) and/or Southern blot method whether or not they would have the injected DNA in their chromosomes. If the presence of the exogenous DNA is confirmed, the transgenic animals will be next analyzed for gene expression by Northern blot hybridization or immunohistochemical methods. In this way, it is principally possible to introduce a certain human hereditary disease-like character into an animal.

Alzheimer's disease (hereinafter called AD) is considered, as mentioned later in detail, to be caused by overexpression of APP (Terry R. D. and Katsman R., *Ann Neurol*, Vol. 14, p. 496-506, 1983). In the brains of patients with AD, there observed neurofibrillary tangles (hereinafter called NFT), paired helical filaments (hereinafter called PHF), a neuritic plaque (or a senile plaque) and deposition of cerebral amyloid which are peculiar to AD and the latter two structures were derived from APP. Moreover, mutations in the APP gene have been recently found in familial Alzheimer's disease (hereinafter called FAD) and in hereditary cerebral amyloid angiopathy. In addition, it has been reported that amyloid plaque core protein (hereinafter called APCP), one of major components of cerebral amyloid, or D-amyloid core protein (later renamed D-protein or D/A4 protein; hereinafter called I/A4 protein) is toxic to neurons (Yankner B. A. et al., *Science*, Vol. 245, p. 417-420, 1989). From these data, it is considered that the most essential approach to elucidate the pathogenesis of AD is to analyze how I/A4 protein is metabolized from APP and finally deposited in a brain.

Unfortunately, a candidate animal model for AD has not yet been known nor created until now and, therefore, it was impossible to prove the hypothesis mentioned above. However, it is now possible to create animals showing a AD-like phenotype (so-called animal models for human AD) by producing transgenic animals into which the APP gene is integrated and the said protein is overexpressed in their brains to cause deposition of cerebral amyloid.

Recently, several reports have been provided on the transgenic mice in which amyloid deposition was observed in their brains by overexpression of the full length or one part of human APP cDNA (Kawabata S. et al., *Nature*, Vol. 345, p. 476-478, 1991; Quon D. et al., *Nature*, Vol. 352, p. 239-241, 1991; Wirak D. O. et

al. Science, Vol. 253, p. 323-325, 1991). However, the report by Kawabata et al. was later found to be not reproducible, and the paper was recently withdrawn (Nature, Vol. 356, p. 265, 1992). Furthermore, the report by Wirak et al. was later found to be misleading because the phenotypic change to AD-like character in APP-overexpressing transgenic mice was not caused by transgene expression (Science, 28, Feb., 1992).

5 On the other hand, there have been several reports which appeared in patent applications to disclose that transgenic model mice for AD are established (for example, see the previously published reports: WO93/14200, WO93/02189, WO92/13069, WO92/06187, WO91/19810, EP451700 and WO 89/06689). However, in each of them, the gene construction was only mentioned and/or only mentioned with indirect proofs that the production of APP (not β /A4 protein) was simply observed. Furthermore, neither a neuronal cell loss

10 nor formation of a neuritic plaque was mentioned in any report. Consequently, it is considered, so far, that the distinct animal models for AD produced by genetic engineering technology are not yet established. On the other hand, the transgenic mice mentioned in the present invention disclose several characteristics similar to symptoms associated with AD. In this sense, they can provide an useful experimental system for elucidating AD pathogenesis and for developing pharmaceuticals to inhibit AD onset and possibly to inhibit

15 neuronal cell death which is closely associated with AD.

As mentioned previously, there are two distinct morphological and pathological changes associated with AD, namely, formation of PHF and deposition of cerebral amyloid. PHF appears more often in other neuronal diseases than AD; whereas, both the neuritic plaque which is an amyloid deposit generated in an intercellular space of neurons and amyloid deposited in the periphery of cerebral blood vessels are

20 considered to be specific for AD. Interestingly, the neuritic plaques are also observed in the brain of aged patients with Down's syndrome (AD is also occurring). Amyloid proteins, a major component of the neuritic plaque, were partially purified and found to consist of mainly β /A4 protein with about 4.2 kD comprising 39 to 42 amino acids (Glennner G. and Wong C.W., BBRC, Vol. 120, p. 1131-1135, 1984). The amino acid sequence of β /A4 protein was determined (Glennner G. and Wong C.W., 1984; Masters C.R. et al., Proc. Nat.

25 Acad. Sci., USA, Vol. 82, p. 4245-4249, 1985) and proved different from the proteins previously reported so far.

A cDNA encoding APP, a relatively large protein precursor including β /A4 protein part, was recently isolated from the cDNA library of human embryonic cerebral tissues. Analysis of the DNA sequence of human APP cDNA revealed that human APP consists of 695 amino acids (hereinafter called A695), and

30 β /A4 protein corresponds to the amino acid positions at 597 to 695 (Kang J. et al., Nature, Vol. 325, p.733-736, 1987). Furthermore, beside A695, successful isolation of other two cDNAs for larger APPs (hereinafter called A751 and A770, respectively) was reported (Kitaguchi et al., Nature, Vol. 331, p. 530-532, 1988). A751 is a protein given with 56 amino acids to A695. The 56 amino acid insert shows a high homology to serine protease inhibitor (hereinafter called KPI) of Kunitz family (Kitaguchi et al., 1988). A770 is a protein

35 that 19 amino acids highly homologous to MRC OX-2 antigen are inserted immediately after the 57 amino acid insert in A751 (Kitaguchi et al., 1988). These A751 and A770 proteins are abundant in many tissues. These three types of proteins are known to be generated by alternative splicing from the same gene, APP gene (Kitaguchi et al., 1988; Ponte P. et al., Nature, Vol. 331, p. 525-527, 1988; Tanz R. et al., Nature, Vol. 331, p. 528-530, 1988). They are thought to be involved in cerebral amyloid deposition, because each has

40 the β /A4 protein portion located on the C-terminal 99 amino acid fragment of APP (the N-terminal 28 amino acid part of this fragment is exposed outside the cell membrane, whereas a domain of β /A4 protein at its C-terminal side, comprising of 11-14 amino acids, exists inside of the cell membrane).

Immunohistochemical studies in the brains of patients with AD by using various antibodies raised against peptides corresponding to the several sites of APP have revealed that neuritic plaques can be

45 stained by these antibodies (Wong C.W. et al., Proc. Nat. Acad. Sci., USA, Vol. 82, p. 8729-8732, 1985; Allsop D. et al., Neurosci. Letter, Vol. 68, p. 252-256, 1986; Shoji M. et al., Brain Res., Vol. 512, p. 164-168, 1990a; Shoji M. et al., Am. J. Pathol., Vol. 137, p. 1027-1032, 1990b; Shoji M. et al., Brain Res., Vol. 530, p. 113-116, 1990c).

Therefore, amyloid proteins composing neuritic plaques in the AD patients can be easily recognized by

50 these antibodies. By using these antibodies, we can trace the localization of APP and its metabolized derivatives in a brain of a transgenic animal overexpressing a human APP gene.

Since APP is widely expressed in many tissues and is also evolutionally conserved (there is a 97% homology at the amino acid level between mouse and human), it is postulated to play an important role on cell-cell interaction and/or neuronal cell differentiation (Shivers B.D. et al., EMBO. J. Vol. 7, p. 1365-1370,

55 1988). Its precise role, however, is still unclear. Recently, it drew an attention that β /A4 protein at lower concentrations serves as a growth stimulating factor for hippocampal matured neuronal cells, but it is neurotoxic at higher concentrations (Yankner B.A. et al., 1989). Interestingly, it was shown that the portion corresponding to the N-terminal 25th to 35th amino acid of β /A4 protein is essential for both growth

stimulating and inhibitory activities, and is homologous to the tachyquinin-type peptides (Yankner B.A. et al., 1989). More interestingly, when the purified $\beta/A4$ protein is injected into a cerebral cortex and a hippocampus of rats, a neuronal cell loss was induced as well as production of abnormally phosphorylated tau protein, a major constituent of PHF (Kowall N.W. et al., Proc. Nat. Acad. Sci., USA, Vol. 88, p. 7247-7251, 1991). These data suggest a close relationship between accumulation of $\beta/A4$ protein and PHF production. As another aspects of the role of APP, it has been reported that the C-terminal region of APP can be phosphorylated by protein kinase C and Ca^{2+} /calmodulin-dependent protein kinase II (Gandy S. et al., Proc. Nat. Acad. Sci., USA, Vol. 85, p. 6218-6221, 1988), and that G_o protein, a major GTP-binding protein present beneath the cell membrane, can interact with APP (Nishimoto I. et al., Nature, Vol. 362, p. 75-78, 1993). These data suggest that APP is involved in signal transduction.

The APP gene is located on the long arm of the 21st chromosome in human (Goldgaber D. et al., Science, Vol. 235, p. 877-880, 1987). Recently, in FAD (AD frequently occurs in people earlier than 65 years old), a mutation (from Val to Ile) was found at the amino acid position of 642 in human APP (based on the data of Kang J. et al., 1987; hereinafter, DNA and amino acid sequences of APP are based on the data of Kang J. et al., 1987) (Goate A. et al., Nature, Vol. 349, p. 704-706, 1991; Naruse S. et al., Lancet, Vol. 337, p. 978-979, 1991; Yoshioka K. et al., BBRC, Vol. 178, p. 1141-1146, 1991; Hardy J. et al., Lancet, Vol. 357, p. 1342-1343, 1991). Furthermore, another mutations (Val to Phe and Val to Gly) at 642 in APP have been found (Murrell J. et al., Science, Vol. 254, p. 97-99, 1991; Chartier-Harlin M.C. et al., Nature, Vol. 353, p. 844-846, 1991). These data suggest that mutation at Val⁶⁴² of APP would play an important role on the pathogenesis of FAD. In the case of Dutch-type AD which is frequently associated with hereditary cerebral hemorrhage, a mutation (Glu⁶¹⁸ to Gln⁶¹⁸) was found within the $\beta/A4$ protein part (Levy et al., Science, Vol. 248, p. 1124-1126, 1990). Furthermore, two mutations (Lys⁵⁹⁵ to Asn⁵⁹⁵ and Met⁵⁹⁶ to Leu⁵⁹⁶) at the N-terminus of $\beta/A4$ protein was recently found in AD patients from a certain Swedish family (Mullan M. et al., Nature, Genet, Vol. 1, p. 345-347, 1992). This type of AD is called Swedish-type AD.

As described above, the molecular biological analysis of APP has been developed, but any effective information is not available yet as to why amyloid is accumulated and deposited in the brain of patients with AD, and how a neuronal cell is degenerated as a result of accumulation of $\beta/A4$ protein.

The present most exciting problem is that what kind of metabolic pathway of APP is profoundly involved in cerebral amyloid deposition. This matter is now being investigated extensively. For example, a membrane-bound C-terminal fraction of APP, 9 KD, could be extracted from human embryonic kidney-derived cell line 293 which had been transfected with expression vector DNA for APP cDNA, and the amino acid sequence of the N-terminus of the 9-kDa peptide was determined. As a result, APP was cleaved at the 16th Lys from the N-terminus of $\beta/A4$ protein (Esch F. S. et al., Science, Vol. 248, p. 1122-1124, 1990). However, for deposition of cerebral amyloid, it requires that APP should be cleaved at both N-terminus and C-terminus of $\beta/A4$ protein and then aggregated. Therefore, insoluble $\beta/A4$ protein is not produced by the metabolic pathway of APP provided Esch et al. Now, involvement of various metabolic systems and their defects would be considered as key factors for amyloid formation, but no clear answers have yet been obtained.

At present, it is considered that there are two pathways for APP processing; namely, 1) so-called secretory pathway, in which APP is processed into the secreted derivatives with molecular weights more than 100 KD ending at the 15th amino acid of $\beta/A4$ protein, and 2) so-called endosomal/lysosomal pathway, in which various APP peptides that are different in size but including a full length $\beta/A4$ protein portion are generated (Golde T.E. et al., Science, Vol. 235, p. 728-730, 1992).

Consequently, it has not yet been dissolved how these two possible APP metabolic pathways are influenced by the mutations in the APP gene found in FAD, Dutch-type and Swedish-type AD. Probably, these APP mutants may allow the APP processing pathway to be entered into the endosomal/lysosomal pathway, not into the secretory pathway. In this connection, a transgenic animal system, in which overexpression of APP mutants are forced to be driven, will provide an useful tool for elucidating the mechanism underlying APP processing.

The present invention provides a tool to analyze the molecular mechanism of APP synthesis. More in detail, it provides the mechanism underlying APP processing after synthesis of APP. More importantly, it provides an in vivo screening system of drugs which can inhibit synthesis and deposition of $\beta/A4$ protein.

A DNA fragment encoding APP which is thought to be related to AD is microinjected into pronuclei of 1-cell embryos in mammalian animals, preferably in mice. These injected embryos are transplanted to the oviducts/uteri of pseudopregnant females and finally transgenic animals can be obtained. These transgenic animals are thought to overexpress the AD-relating APP. The injected DNA contains an ubiquitous promoter to drive expression of the target protein in various types of the cells in transgenic mice. Since $\beta/A4$ protein is generated from the C-terminal region of APP, overexpression of the C-terminus fragment of APP is

considered to stimulate the formation of β /A4 protein leading to a neuronal cell loss and a neuritic plaque formation, similar to AD

The important point of the present invention is that overexpression of the C-terminal region of APP which includes the β /A4 protein portion is possible in neuronal cells and other types of cells under the control of a strong and ubiquitous promoter. Then, as a result, the following phenotypic alteration can be elicited; AD-specific amyloid deposition at hippocampus, appearance of abnormally phosphorylated tau protein, increase in the number of glial cells, alteration in the alternative splicing pattern of endogenous mouse APP transcripts, neuronal cell death near hippocampus and reduced behavioral activity. Another important point of the present invention is that transgenic mice having the DNA sequence encoding APP mutants, in which at least one amino acid replacement occurs in β /A4 protein, could be successfully created. With this invention, the massive accumulation of a cerebral amyloid would occur, because the mutant APPs tend to be frequently transferred to the endosomal/lysosomal pathway of APP and/or possibly become insensitive against proteolytic cleavage leading to formation of β /A4 protein. Accordingly, the transgenic mice disclosed in the present invention provide an useful system to analyze the interaction between APP and APP-processing protease in vivo, and the interaction between the endogenous mouse APP and the introduced human APP. They will also be utilized for screening anti-AD drugs in vivo.

The aim of the present invention is to provide transgenic animals having a recombinant DNA, a DNA sequence necessary for allowing the C-terminal region of normal or mutant APP (including the β /A4 protein portion) to express strongly in neuronal cells and other non-neuronal cells. The usefulness of the present invention is that these transgenic animals can be used for analyzing the mechanism of AD pathogenesis and for screening anti-AD reagents in vivo.

The characteristics of the present invention is that the transgenic animals described here are defined as "true" animal models for AD, compared with any known APP-expressing transgenic animals, because the present transgenic animals exhibit a series of symptoms similar to AD (i.e., massive production of APP, appearance of abnormally phosphorylated tau protein, increase in the number of glial cells, neuronal cell death, etc.).

Therefore, one embodiment of the present invention is a transgenic mammalian animal excluding human containing a DNA encoding the C-terminal region of human APP containing about the first 99 to 103 amino acids of APP, in particular the amino acid sequence of I.D. NO: 4 or 10; said DNA is integrated into the somatic and germ cells of said animal. Furthermore, the transgenic animals contain mutant human APP containing the amino acid sequence I.D.NO: 6 wherein glutamic acid at position 22 of SEQ I.D.NO: 4 is converted to glutamine, the amino acid sequence I.D.NO: 8 wherein valine at position 46 of SEQ I.D.NO: 4 is converted to isoleucine; the amino acid sequence I.D. NO: 12 wherein lysine at position 3 of SEQ I.D.NO: 10 is converted to asparagine and methionine at position 4 of SEQ I.D.NO: 10 is converted to leucine.

A preferred embodiment of the present invention is a transgenic animal containing a DNA integrated into the somatic and germ cells wherein said DNA encodes a signal peptide, in particular a signal peptide of human β -amyloid precursor protein, more particular a signal peptide with the amino acid sequence of I.D.NO: 2 and the above-mentioned C-terminal regions of human APP.

Another embodiment of the present invention is a transgenic animal wherein said integrated DNA is controlled by an ubiquitous promoter, in particular the β -actin promoter, and an enhancer, in particular the cytomegalovirus enhancer.

Yet another embodiment of the invention refers to a method of producing a transgenic animal of the present invention wherein the exogenous DNA is microinjected into the nucleic of 1-cell stage embryos or wherein the exogenous DNA is introduced into preimplantation embryos with the aid of retroviral vector DNA.

The transgenic animal can be used as an Alzheimer's disease model as already explained above because the animal of the present invention showed the following histopathological characteristics in the hippocampus;

- 1) synthesis in large quantity of C-terminus peptide of β -amyloid precursor protein,
- 2) death of neuronal cell in pyramidal cells at CA regions,
- 3) increase of glial cells, and
- 4) deposition of abnormally phosphorylated tau protein.

Therefore, another embodiment refers also to the use of the transgenic animals of the present invention for the screening of drugs against Alzheimer's disease.

This invention shall be more illustratively explained by the following examples.

Brief Explanation of Drawings

Fig. 1 shows a map for plasmid pBsCAG-2 having cytomegalovirus enhancer/chicken β -actin promoter.

Fig. 2 shows transgenes in which cytomegalovirus enhancer/chicken β -actin promoter element is
5 combined with NOR β , D β , FAD β , Δ NOR β and NL β .

Fig. 3 shows a result from Northern blot analysis of various tissues from β A-NOR β transgenic mice (1102 and 0304) and a non-transgenic mouse. The size of molecular weight is shown as kb and the molecular weight markers are described in the right side of the drawing.

Fig. 4 shows a result from Western blot analysis of cerebral extracts from β A-NOR β transgenic mice
10 and a non-transgenic mouse. The antibody used is anti-APP antibody, W61C.

Fig. 5 shows microphotographs showing Nissul-staining of hippocampus of β A-NOR β -304 transgenic mouse brain (A) and a non-transgenic mouse brain (B)

Fig. 6 shows microphotographs showing immuno reaction of a cortex region with β A-NOR β -0304 transgenic animal brain (A), and a non-transgenic mouse brain (B), by using anti-APP antibody, W61C.

Fig. 7 shows microphotographs of immuno reactive products produced by anti-GFAP antibody in β A-NOR β -0304 transgenic animal brain (A) and a non-transgenic mouse brain (B).

Fig. 8 shows microphotographs of immunoreactive products produced by anti-tau antibody, β 1-28, in β A-NOR β -0304 transgenic animal brain (A) and a non-transgenic mouse brain (B).

Fig. 9 shows pictures of β A-NOR β -0304 transgenic mouse (center in the figure) and a non-transgenic
20 mouse (upper in the figure) (A) and of β A-NOR β -0304 transgenic mouse (B).

Examples

In this invention, the following examples are intended to disclose and describe completely how to make
25 DNA sequences, fusion gene constructs, transgenic mice, etc. However, it should not be construed that the invention is limited to these specific examples.

Example 1 Construction of plasmids p β A/NOR β , p β A/FAD β , p β A/D β , p β A/ Δ NOR β and p β A/NL β

30 The target gene to be expressed in mice was constructed as follows; the sequence encoding a signal peptide (at amino acid positions of 1-17) of normal human APP and the sequence encoding the C-terminal portion including the β A4 protein portion (at amino acid positions of 597-695). This fusion gene (hereafter called NOR β) was synthesized according to the method of Horton R.M. et al. (Gene, Vol. 77, p. 61-68, 1989). First, human brain cDNA library was synthesized by RT (reverse transcription)-PCR method from an
35 embryonic human brain poly(A) RNA (#6516-1; Clontech). The primers used were reverse primer BAPP-6 (SEQ ID No.: 7), sense primer BAPP-7 (SEQ ID No.: 8), sense primer BAPP-10 (SEQ ID No.: 9) and reverse primer BAPP-12 (SEQ ID No.: 10). By using these primers, NOR β was successfully synthesized. The resulting NOR β was next fractionated through electrophoresis in a 2% agarose gel. The isolated NOR β was digested with XbaI and inserted into the XbaI site of a cloning vector pGEM3Z(-) (Promega) to create
40 pGEM3Z/NOR β . This recombinant plasmid was then amplified in *E. coli* and purified. The purified plasmid DNA was sequenced by a dideoxy chain-termination method (Sanger et al., Proc. Nat. Sc., USA, Vol. 74, p. 5463-5468, 1977), and was confirmed that the inserted NOR β sequence had the correct sequence as previously reported (Kang J. et al., 1987).

D β (a DNA sequence formed by combining SEQ ID No.: 1 with SEQ ID No.: 3) and FAD β (a DNA
45 sequence formed by combining SEQ ID No.: 1 with SEQ ID No.: 4) are basically the same as NOR β , except that 1) D β has a mutation (Glu⁶¹⁸ to Gln⁶¹⁸) in APP which is found in Dutch families with a hereditary amyloid angiopathy and FAD β a mutation (Val⁶⁴² to Ile⁶⁴²) in APP which is found in families with FAD, and 2) both D β and FAD β have additional about 30 bp 3' non-translated region of human APP cDNA (Kang J. et al., 1987) at their 3' side. These were synthesized by PCR method of Horton et al. (1989) from the human
50 cDNA library as mentioned previously. In case of synthesis of D β , reverse primer BAPP-8 (SEQ ID No.: 11), sense primer BAPP-2 (SEQ ID No.: 12) and reverse primer BAPP-15 (SEQ ID No.: 13) as well as BAPP-10, BAPP-6 and BAPP-7 were used. In case of FAD β , reverse primer BAPP-3 (SEQ ID No.: 14), sense primer BAPP-9 (SEQ ID No.: 15) and BAPP-15 as well as BAPP-10, BAPP-6 and BAPP-7 were used.

Δ NOR β (a DNA sequence for Met is added to the N-terminal portion for the sequence of SEQ ID No.: 5
55 peptide) is basically the same as NOR β , except that a sequence for the signal peptide consisting of 17 amino acids is missing. Δ NOR β was synthesized by PCR using pGEM3Z/NOR β as a template DNA. The primers used were sense primer BAPP-13 (SEQ ID No.: 16) and BAPP-12. The amplified fragment was then cloned into pGEM3Z(-). The insert was sequenced to confirm that the sequence of the insert was correct.

NL β (a DNA sequence for Met was added to the N-terminal portion of the sequence encoding a peptide described in SEQ ID No. 6) was PCR-amplified as with the synthesis of Δ NOR β , using sense primer BAPP-14 (SEQ ID No.: 17) and BAPP-12. The amplified fragment was cloned into PGEM3Z (-). The insert was sequenced to confirm that the sequence of the insert was correct. NL β , a mutant APP gene found in Swedish-type AD, has two mutations (Lys⁵⁹⁵ to Asn⁵⁹⁵ and Met⁵⁹⁶ to Leu⁵⁹⁶) in the N-terminal region of β /A4 protein.

Expression vectors to express the genes described above were constructed as follows: A 2.3-kb fragment containing cytomegalovirus enhancer/chicken β -actin promoter element was isolated by digestion with Sall/PstI of a mammalian expression vector pCAGGS (Niwa H et al., Gene, Vol. 108, p. 193-200, 1991) and inserted into the Sall/PstI sites of a cloning vector pBluescript (Stratagene) to create pBsCAG-2 (Fig. 1). In the 2.3-kb fragment containing the above described enhancer/promoter, a part of rabbit β -globin gene (composed of the 2nd intron, the 3rd exon and 3' non-translated region) is also included. Generally, a target gene (i.e., cDNA) to be expressed can be inserted into the EcoRI site of the 3rd exon of rabbit β -globin gene in pBsCAG-2. The above described NOR β , FAD β , D β , Δ NOR β and NL β genes were inserted into pBsCAG-2 to create p β /NOR β , p β A/FAD β , p β A/D β , p β A/ Δ NOR β and p β A/NL β which will be used for expression of the target genes in transgenic mice (Fig. 2). For DNA introduction into mouse 1-cell stage embryos, the transgene was isolated from each fusion construct by digestion with Sall/BamHI and used. DNA digestion, ligation and isolation. Also, DNA sequence at the junctional region between the insert and the vector was confirmed by sequencing.

Example 2 Recovery of 1-Cell Stage Embryo and DNA Introduction into It

One-cell stage embryos were recovered from the oviducts of B6C3F1 female mice that had been already mated with male mice. The recovered embryos are still in an early stage of pronucleate stage. Therefore, both ale and female pronuclei can be easily distinguishable because they are separated from each other. Cumulus cells surrounding oocytes were removed by hyaluronidase treatment, washed properly and incubated at 37°C in an atmosphere of 5% CO₂ in air, for a certain time prior to DNA injection. Preferably, it is kept in a drop (50 μ l) of M-16 egg culture medium (Whittingham D.G., J. Reprod. Fert., Vol. 4, p. 7-21, 1971) covered with paraffin oil on a bacteriological dish with 30 mm diameter (No. 333656, Nunc). The fusion construct containing a transgene was prepared by the above-mentioned method. Any of the above-mentioned fusion constituents can be cloned, and can be introduced into the pronuclei of 1-cell stage embryos according to the method mentioned herein.

Next, the explanation shall be given in detail on the introduction of DNA obtained from a NOR β -expression vector (p β A/NOR β). This method can also be applied for other fusion constructs than p β A/NOR β .

First of all, p β A/NOR β was extracted after cloning into the host *E. coli* and subsequent cultivation. For further purification, the extracts were ultra-centrifugated in cesium chloride and dialyzed after removal of ethidium bromide. Transgene can be isolated after digestion of these purified plasmid DNAs with certain restriction enzymes (in this case Sall and BamHI were used) and subsequent electrophoresis in a 0.8% agarose gel. The obtained transgene was microinjected into 1-cell stage embryos by using an injection pipette with 1 μ m outside diameter (Hogan B. et al., Manipulating the Mouse Embryo, 1986). About 10 μ l of DNA solution containing transgenes (about 1,000 copies of transgenes per pl) were sucked and the DNA was injected into the male pronucleus. The injected embryos were incubated for several hours to one day and then transplanted to the oviducts of pseudopregnant ICR foster mothers of Day 1 of pregnancy (the day when a vaginal plug is recognized is defined as Day 1 of pregnancy). The transplanted foster mothers were fed until a delivery of fetus. After delivered, neonates were nursed by the foster mothers for one month until weaning. Then, they were served for Southern blot analysis of a tail DNA. The F₀ (founder) mouse, judged as transgenic, was mated with other non-transgenic mouse to obtain F1 transgenic offspring. These F1 transgenic offspring can be cryopreserved in a form of eggs or spermatozoa. After this, all the F1 transgenic offspring and their non-transgenic littermates were killed on 10 to 30 weeks after birth for Northern blot hybridization and pathological analyses.

As one of the examples, the results obtained from the injection of β -NOR β transgene into mouse 1-cell stage embryos are shown in Table 1. Illustrated therein are the number of neonates per the number of surviving fetuses after DNA injection and transfer to recipients and the number of F₀ mice judged as transgenic.

Table 1

| Productive Efficiency of Transgenic Mice having β A-NOR β transgene | | |
|---|---|-------------------------------|
| Transgene | Number of neonates/Number of transplanted embryos (%) | Number of Transgenic mice (%) |
| β A-NOR β | 120/560 (21) | 35 (29) |

As shown in Table 1, 35 of 120 mice born were transgenic. When these transgenic mice were continuously observed, one line (0304) became inactive around 10 weeks after birth and another one line (1102) showed hydrocephaly. The other transgenic animals looked normal until about 10 to 30 weeks after birth. Gametes were collected and deep-frozen before sampling for molecular and pathological analyses. After this, brains from these transgenic samples were screened by Northern and Western blot analyses to identify NOR β -higher expressing lines and 5 lines showing strong expression of NOR β (0202, 0304, 1002, 1102 and 1301) were finally selected. The following is mainly on the results from the analysis of these 5 lines.

Example 3 Transgene-Derived mRNA Expression

The transgene-derived mRNA expression was analyzed by Northern blot hybridization for β A-NOR β transgenic lines (including 0304 and 1102). Total cellular RNA was isolated from organs (including brains) of transgenic and non-transgenic mice. The isolated RNA (20 μ g) was electrophoresed in 1.1% agarose/1.1 M formaldehyde gel and then blotted onto a nylon membrane filter. Prehybridization was carried out for 2 hours at 42°C in a hybridization buffer [5XSSC (1XSSC = 0.15M NaCl, 15mM Na-citrate, pH 7.4), 50% formamide, 5mM EDTA, 5mg/ml heat-denatured salmon DNA and 5X Denhardt's solution]. The DNA probe (containing a NOR β fragment) was heat-denatured after labelling with ³²P by random prime labelling method and added to the hybridization buffer. Hybridization was performed for 18 hours at 42°C. The filters were washed for 20 minutes at 56°C in a solution containing 0.1XSSC and 0.1% SDS. The filters were exposed to Kodak XAR-5 film with a intensifying screen for 24 to 72 hours at -80°C. An example of the Northern blot analysis is shown in Fig. 3. RNAs loaded were from NOR β -higher expressing lines (0304 and 1102) and a non-transgenic mouse. The organs investigated were brain, liver, kidney, intestine and testis. In the brain of 0304 line, there observed about 10 times higher expression of transgene-derived mRNA (about 1 kb in size) than that of endogenous mouse A695 mRNA (about 3.4kb in size). The level of NOR β mRNA in the 1102 sample was slightly lower than that in the 0304 sample. However, non-transgenic sample had no transgene-derived mRNA. A similar tendency was observed in other organs. Interestingly, there was an increase in the amount of A695 mRNA in the transgenic mice (for example, see the liver samples of 1102 and 0304). Similar increase in the level of A751 (about 3.8 kb in size) and A770 (about 3.85 kb in size) mRNAs was observed (for example, see the brain samples of 1102 and 0304). It is considered that this may reflect the altered alternative splicing pattern of endogenous mouse APP mRNA, possibly due to overexpression of the exogenous NOR β .

Example 4 Western Blot Analysis

The expression pattern of APP in the brains from β A-NOR β transgenic mice and non-transgenic mouse (control) was determined by Western blot analysis. Protein homogenate was prepared from a whole or 3/4 brain according to the method of Shivers B.D. et al. (1988). A sample (50 μ g) was electrophoresed in 10/16% Tris-tricine SDS gel and transferred to immobilm-P membranes by electroblotting. The blot was reacted with the anti-APP antibody, W61C, diluted at 1/500 (rabbit antibodies raised against the C-terminal peptide between amino acid positions of 660 and 695 in APP; Shoji M. et al., 1990c) in order to detect APP using non-R1 ECL detection system (Amersham).

An example of Western blot analysis is shown in Fig. 4. In Fig. 4, the results of a total of 11 transgenic mice and a non-transgenic mouse are shown. Namely, some bands near about 120-kDa, corresponding to the previously reported mammalian animal APP isoforms, were detected in the brain and other organs from the non-transgenic control mouse and transgenic mice. Furthermore, a remarkable increase in the level of NOR β -derived protein (11.4 Kd) was observed. Especially, a high expression (5 to 6 times) was observed in the transgenic samples from 0202, 1002 and 1301 lines. However, none of bands at 4.2 kD which corresponds to β /A4 protein was not detectable by this procedure. It is considered that β /A4 protein is not

produced in the transgenic brains examined or may be scarce if produced.

Example 5 Immunohistochemical Analysis of Mouse Brains using Antibodies

5 In order to analyze the transgene expression in detail at tissue or cellular level, immunohistochemical staining was performed for organs (including brain) from transgenic and non-transgenic mice by using anti-APP antibodies. The mice investigated were 3 lines having β A-NOR β and non-transgenic mice.

Mice were anaesthetized with pentobarbital and organs were excised. These organs were then fixed in 4% paraformaldehyde (in PBS) for 1-3 days, embedded in paraffin and sectioned at 5 μ m thickness. The
10 specimens were dewaxed, dehydrated, treated with 0.5% periodic acid for 0.5 hours, blocked with normal goat serum and reacted with the antibody diluted to 1/500. The reaction was carried out for 3 hours at room temperature, reacted with biotinylated anti-rabbit IgG for 2 hours at room temperature, and then reacted with ABC (avidin-biotin peroxidase complex). These reactions were carried out according to the procedure recommended by the manufacturer (ABC Kit; Vector Co., Burlingame, USA). Peroxidase activity can be
15 visualized by incubation with a substrate, 3,3'-diamino-benzidine (DAB)/NiCl₂. Counterstaining was performed with methyl green. Some of the specimens were Nissul-stained in order to detect neuronal cells more clearly.

Nissul-staining of the brains from transgenic mice of β A-NOR β -0304 line and a non-transgene mouse revealed that a neuronal cell loss was found in the transgenic samples; especially remarkable in the
20 pyramidal layer of CA3 region of hippocampus as shown in Fig. 5.

Immunohistochemical staining of the brains from β A-NOR β -0304 transgenic and its non-transgenic littermate by W61C, one of the anti-APP antibodies revealed that a strong immuno-reaction was observed in neuronal cells of a cerebral cortex and a hippocampus of transgenic mice, compared with those from the non-transgenic mice as shown in Fig. 6. In addition, positive reaction was also observed in many neuronal
25 processes. Similar observation was made by using other antibodies, W63N, raised against the N-terminal region of APP peptide (18th to 38th) (Shoji M. et al, 1990c). However, mesencephalon, brain stem and cerebellum were unreactive with these antibodies.

A remarkable increase in the number of glial cells was observed in the cortex, hippocampus and forebrain basement of the transgenic mice when evaluated by anti-GFAP (glial fibrillary acidic protein)
30 antibody which specifically recognizes glial cells as shown in Fig. 7. This increase in the number of glial cells is considered to be closely associated with AD (Beach T.G. et al., Glia, Vol. 2, p. 420-436, 1989). As perhaps speculated from the Drawing 5, glial cells may proliferate in order to compensate the space generated along with a neuronal cell loss.

When brain specimens from β A-NOR β -0304 transgenic and non-transgenic mice were reacted with the
35 antibody β 1 - 28 (Ihara r. et al, Nature, Vol. 304, p. 727-730, 1983) which specifically recognizes the abnormally phosphorylated tau protein, cells within and around the hippocampal region of the transgenic mice were stained as shown in Fig. 8(A). No positive reaction was observed in the non-transgenic brains as shown in Fig. 8(B).

Whole pictures of β A-NOR β -0304 transgenic mouse and its non-transgenic littermate are shown in Fig.
40 9. Fig. 9(A) shows β A-NOR β -0304 transgenic mouse (center in the figure) and non-transgenic mouse (upper in the figure) and Fig. 9(B) shows β A-NOR β -0304 transgenic mouse alone.

The transgenic mice described in this invention can be utilized for screening drugs that are able to decrease parameters (i.e., anti- β /A4 protein antibody-reactive substance, anti-abnormally phosphorylated tau protein antibody-reactive substance, etc.) associated with AD. For example, the drug to be assayed can
45 be administrated simultaneously to both the transgenic and non-transgenic control animals. This drug shall be administrated continuously for a period sufficient to influence the above-described parameters in animal brains or to inhibit neuronal cell death. After administration of the drug, mice will be analyzed for their brains histologically and molecular biologically. By comparing the above described parameters between transgenic and control animals, a decision whether the drug used is effective or not can be made.

50

55

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT:
 (A) NAME: Hoechst Japan Limited
 (B) STREET: New Hoechst Building
 (C) CITY: 10-16, Akasaka 8-chome
 (D) STATE: Minato-ku, Tokyo
 (E) COUNTRY: 107 Japan
 10 (F) POSTAL CODE (ZIP): -
 (G) TELEPHONE: (03) 3470-5137
 (H) TELEFAX: (03) 3479-7859
 (I) TELEX: -
- (ii) TITLE OF INVENTION: Transgenic Animal for Alzheimer's Disease
- 15 (iii) NUMBER OF SEQUENCES: 23
- (iv) COMPUTER READABLE FORM:
 (A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 20 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 51 base pairs
 25 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: NO
- 30 (iii) ANTI-SENSE: YES
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: homo sapiens
 (B) STRAIN: human brain
- 35 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..51
 (D) OTHER INFORMATION: /note= "1. human beta-amyloid precursor; 2. signal peptide"
- 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
- | | |
|---|----|
| ATG CTG CCC GGT TTG GCA CTG CTC CTG CTG GCC GCC TGG ACG GCT CGG | 48 |
| Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg | |
| 1 5 10 15 | |
| GCG | 51 |
| Ala | |
- 45

(2) INFORMATION FOR SEQ ID NO: 2:

- 50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- 55

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

5 Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
1 5 10 15

Ala

10 (2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 297 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

20 (iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: homo sapiense

(B) STRAIN: human brain

25 (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..297

(D) OTHER INFORMATION: /note= "1. human beta-amyloid precursor; 2. C-terminal peptide"

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GAT GCA GAA TTC CGA CAT GAC TCA GGA TAT GAA GTT CAT CAT CAA AAA 48
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1 5 10 15

35 TTG GTG TTC TTT GCA GAA GAT GTG GGT TCA AAC AAA GGT GCA ATC ATT 96
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
20 25 30

GGA CTC ATG GTG GGC GGT GTT GTC ATA GCG ACA GTG ATC GTC ATC ACC 144
Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr
35 40 45

40 TTG GTG ATG CTG AAG AAG AAA CAG TAC ACA TCC ATT CAT CAT GGT GTG 192
Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val
50 55 60

45 GTG GAG GTT GAC GCC GCT GTC ACC CCA GAG GAG CGC CAC CTG TCC AAG 240
Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys
65 70 75 80

ATG CAG CAG AAC GCC TAC GAA AAT CCA ACC TAC AAG TTC TTT GAG CAG 288
Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln
85 90 95

50 ATG CAG AAC 297
Met Gln Asn

55

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 99 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

10 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
 1 5 10 15
 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
 20 25 30
 15 Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr
 35 40 45
 Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val
 50 55 60
 20 Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys
 65 70 75 80
 Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln
 85 90 95
 Met Gln Asn

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 297 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: homo sapiens
 (B) STRAIN: human brain

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..297
 (D) OTHER INFORMATION: /note= "1. human beta-amyloid precursor; 2. C-terminal peptide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

48 GAT GCA GAA TTC CGA CAT GAC TCA GGA TAT GAA GTT CAT CAT CAA AAA
 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
 1 5 10 15
 50 TTG GTG TTC TTT GCA CAA GAT GTG GGT TCA AAC AAA GGT GCA ATC ATT 96
 Leu Val Phe Phe Ala Gln Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
 20 25 30

GGA CTC ATG GTG GGC GGT GTT GTC ATA GCG ACA GTC ATC GTC ATC ACC 144
 Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr
 35 40 45
 5 TTG GTG ATG CTG AAG AAG AAA CAG TAC ACA TCC ATT CAT CAT GGT GTG 192
 Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val
 50 55 60
 GTG GAG GTT GAC GCC GCT GTC ACC CCA GAG GAG CGC CAC CTG TCC AAG 240
 Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys
 65 70 75 80
 10 ATG CAG CAG AAC GGC TAC GAA AAT CCA ACC TAC AAG TTC TTT GAG CAG 288
 Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln
 85 90 95
 ATG CAG AAC 297
 15 Met Gln Asn

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 99 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

25 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
 1 5 10 15
 Leu Val Phe Phe Ala Gln Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
 20 25 30
 30 Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr
 35 40 45
 Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val
 50 55 60
 35 Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys
 65 70 75 80
 Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln
 85 90 95
 Met Gln Asn

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 297 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: homo sapiense
(B) STRAIN: human brain

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..297

(D) OTHER INFORMATION: /note= "1. human beta-amyloid precursor; 2. C-terminal peptide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

```

10  GAT GCA GAA TTC CGA CAT GAC TCA GGA TAT GAA GTT CAT CAT CAA AAA      48
    Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
     1          5          10          15

    TTG GTG TTC TTT GCA GAA GAT GTG GGT TCA AAC AAA GGT GCA ATC ATT      96
    Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
             20          25          30

    GGA CTC ATG GTG GGC GGT GTT GTC ATA GCG ACA GTG ATC ATC ATC ACC      144
    Gly Leu Met Val Gly Gly Val Ile Ala Thr Val Ile Ile Ile Thr
             35          40          45

    TTG GTG ATG CTG AAG AAG AAA CAG TAC ACA TCC ATT CAT CAT GGT GTG      192
    Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val
             50          55          60

    GTG GAG GTT GAC GCC GCT GTC ACC CCA GAG GAG CGC CAC CTG TCC AAG      240
    Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys
             65          70          75          80

    25  ATG CAG CAG AAC GGC TAC GAA AAT CCA ACC TAC AAG TTC TTT GAG CAG      288
        Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln
             85          90          95

    30  ATG CAG AAC      297
        Met Gln Asn

```

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 99 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

```

40  Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
     1          5          10          15

    Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
             20          25          30

    45  Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Ile Ile Thr
        35          40          45

    Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val
        50          55          60

    50  Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys
        65          70          75          80

```

Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln
 85 90 95

Met Gln Asn

5

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 309 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

15

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: homo sapiense
 (B) STRAIN: human brain

20

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..309
 (D) OTHER INFORMATION: /note= "1. human beta-amyloid precursor; 2. C-terminal peptide"

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

| | |
|--|-----|
| GAA GTG AAG ATG GAT GCA GAA TTC CGA CAT GAC TCA GGA TAT GAA GTT | 48 |
| Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val | |
| 1 5 10 15 | |
| CAT CAT CAA AAA TTG GTG TTC TTT GCA GAA GAT GTG GGT TCA AAC AAA | 96 |
| His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys | |
| 20 25 30 | |
| GGT GCA ATC ATT GGA CTC ATG GTG GGC GGT GTT GTC ATA GCG ACA GTG | 144 |
| Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val | |
| 35 40 45 | |
| ATC GTC ATC ACC TTG GTG ATG CTG AAG AAG AAA CAG TAC ACA TCC ATT | 192 |
| Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile | |
| 50 55 60 | |
| CAT CAT GGT GTG GTG GAG GTT GAC GCC GCT GTC ACC CCA GAG GAG CGC | 240 |
| His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg | |
| 65 70 75 80 | |
| CAC CTG TCC AAG ATG CAG CAG AAC GGC TAC GAA AAT CCA ACC TAC AAG | 288 |
| His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys | |
| 85 90 95 | |
| TTC TTT GAG CAG ATG CAG AAC | 309 |
| Phe Phe Glu Gln Met Gln Asn | |
| 100 | |

50

55

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 103 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

10 Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
 1 5 10 15
 His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
 20 25 30
 15 Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
 35 40 45
 Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
 50 55 60
 His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
 20 65 70 75 80
 His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
 85 90 95
 Phe Phe Glu Gln Met Gln Asn
 100

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 309 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: homo sapiense
 (B) STRAIN: human brain

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..309
 (D) OTHER INFORMATION: /note= "1. human beta-amyloid precursor; 2. C-terminal peptide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

48 GAA GTG AAT CTG GAT GCA GAA TTC CGA CAT GAC TCA GGA TAT GAA GTT
 Glu Val Asn Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
 1 5 10 15
 50 CAT CAT CAA AAA TTG GTG TTC TTT GCA GAA GAT GTG GGT TCA AAC AAA
 His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
 20 25 30

GGT GCA ATC ATT GGA CTC ATG GTG GGC GGT GTT GTC ATA GCG ACA GTG 144
 Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
 35 40 45
 5 ATC GTC ATC ACC TTG GTG ATG CTG AAG AAG AAA CAG TAC ACA TCC ATT 192
 Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
 50 55 60
 CAT CAT GGT GTG GTG CAG GTT GAC GCC GCT GTC ACC CCA GAG GAG CGC 240
 His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
 65 70 75 80
 10 CAC CTG TCC AAG ATG CAG CAG AAC GGC TAC GAA AAT CCA ACC TAC AAG 288
 His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
 85 90 95
 TTC TTT GAG CAG ATG CAG AAC 309
 Phe Phe Glu Gln Met Gln Asn
 15 100

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 103 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
 25 Glu Val Asn Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
 1 5 10 15
 His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
 20 25 30
 30 Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
 35 40 45
 Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
 50 55 60
 35 His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
 65 70 75 80
 His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
 85 90 95
 40 Phe Phe Glu Gln Met Gln Asn
 100

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (iii) HYPOTHETICAL: YES
 (iii) ANTI-SENSE: NO
 55

(vi) ORIGINAL SOURCE:
(A) ORGANISM: none
(B) STRAIN: none

5 (ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 1..26
(D) OTHER INFORMATION: /note= "reverse primer DNA, termed
"BAPP-6""

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

TTCTGCATCC GCCCGAGCCG TCCAGG

26

(2) INFORMATION FOR SEQ ID NO: 14:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: NO

25 (vi) ORIGINAL SOURCE:
(A) ORGANISM: none
(B) STRAIN: none

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 1..29
30 (D) OTHER INFORMATION: /note= "sense primer DNA, termed
"BAPP-7""

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

GCTCGGGCGG ATGCAGAATT CCGACATGA

29

35

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
40 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

45

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: none
(B) STRAIN: none

50 (ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 1..25

55

(D) OTHER INFORMATION: /note= "sense primer DNA, termed
"BAPP-10"

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CTCTAGAGAT GCTGCCCGGT TTGGC

25

(2) INFORMATION FOR SEQ ID NO: 16:

10

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: NO

20

(vi) ORIGINAL SOURCE:
(A) ORGANISM: none
(B) STRAIN: none

25

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 1..30
(D) OTHER INFORMATION: /note= "reverse primer DNA, termed
"BAPP-12"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GGCTCTAGAG CATGTTCTGC ATCTGCTCAA

30

30

(2) INFORMATION FOR SEQ ID NO: 17:

35

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

40

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: none
(B) STRAIN: none

45

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note= "reverse primer DNA, termed
"BAPP-8"

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

GTCTTGTGCA AAGAACACCA A

21

55

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: none
- (B) STRAIN: none

(ix) FEATURE:

- (A) NAME/KEY: exon
- (B) LOCATION: 1..21
- (D) OTHER INFORMATION: /note= "sense primer DNA, termed
"BAPP-2"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

TTGGTGTCTTCT TTGCACAAGA T

21

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: none
- (B) STRAIN: none

(ix) FEATURE:

- (A) NAME/KEY: exon
- (B) LOCATION: 1..24
- (D) OTHER INFORMATION: /note= "reverse primer DNA, termed
"BAPP-15"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

GGATCCAAC TACAGAGGCTG CTGT

24

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: none
(B) STRAIN: none

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note= "reverse primer DNA, termed
"BAPP-3"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

GGTGATGATG ATCACTGTGC C

21

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: none
(B) STRAIN: none

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note= "sense primer DNA, termed
"BAPP-9"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GCGACAGTGA TCATCATCAC C

21

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: none
(B) STRAIN: none

(ix) FEATURE:

- (A) NAME/KEY: exon
(B) LOCATION: 1..38
(D) OTHER INFORMATION: /note= "sense primer DNA, termed
"BAPP-13""

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GGCTCTAGAG ATGGAAGTGA AGATGGATGC AGAATTCC

38

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: none
(B) STRAIN: none

(ix) FEATURE:

- (A) NAME/KEY: exon
(B) LOCATION: 1..38
(D) OTHER INFORMATION: /note= "sense primer DNA, termed
"BAPP-14""

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:


GGCTCTAGAG ATGGAAGTGA ATCTGGATGC AGAATTCC


38

Claims

1. A transgenic mammalian animal excluding human containing a DNA encoding the C-terminal region of human β -amyloid precursor protein (APP) containing about the first 99 to 103 amino acids of APP; said DNA is integrated into the somatic and germ cells of said animal.
2. A transgenic animal according to claim 1, wherein the C-terminal region of human APP contains the amino acid sequence I.D. NO: 4, I.D. NO: 6, I.D. NO: 8, I.D. NO: 10 or I.D. NO: 12.
3. A transgenic animal according to claims 1 or 2, wherein a DNA encoding a signal peptide is connected with said DNA encoding human APP.
4. A transgenic animal according to claim 3, wherein the signal peptide is the signal peptide of human APP.
5. A transgenic animal according to claim 4, wherein the signal peptide contains the amino acid sequence I.D. NO: 2.

6. A transgenic animal according to claims 1-5, wherein the transcription of said DNAs is controlled by an ubiquitous promoter and enhancer
7. A transgenic animal according to claim 6, wherein said promoter is the β -actin promoter and independently thereof the enhancer is the cytomegalovirus enhancer.
8. A transgenic animal according to claims 1-7, wherein the transgenic animal is a mouse.
9. Method of producing a transgenic animal according to claims 1-8, wherein the exogenous DNA of claims 1-8 is microinjected into the nucleic of 1-cell stage embryos or wherein said exogenous DNA is introduced into preimplantation embryos with the aid of retroviral vector DNA.
10. Use of a transgenic animal according to claims 1-8 for the screening of drugs against Alzheimer's disease.

**Fig. 1**



En : Cytomegalovirus enhancer

β A : Chicken β - actin promotor

▨ : APP coding region

SP : Signal peptide

β / A4 : C - terminal region of APP corresponding to β / A4 protein


* : Glu \rightarrow Gln conversion at codon No. 22 in β / A4 protein

† : Val \rightarrow Ile conversion at codon No. 50 in β / A4 protein

** : Lys \rightarrow Asn conversion at codon No. 3 and Met \rightarrow Leu


conversion at codon No. 4 in β / A4 protein

Fig. 2



| | | | |
|----|-----|----|-----------|
| 1, | 6, | 11 | Brain |
| 2, | 7, | 12 | Liver |
| 3, | 8, | 12 | Kidney |
| 4, | 9, | 13 | Intestine |
| 5, | 10, | 15 | Testis |

Fig. 3



- | | | |
|----|-------------------------|----------|
| 1 | Transgenic animal | (0202) |
| 2 | Transgenic animal | (0305) |
| 3 | Transgenic animal | (0401) |
| 4 | Transgenic animal | (0804) |
| 5 | Transgenic animal | (1002) |
| 6 | Transgenic animal | (1004) |
| 7 | Transgenic animal | (1301) |
| 8 | Transgenic animal | (1303) |
| 9 | Transgenic animal | (1402) |
| 10 | Transgenic animal | (1501) |
| 11 | Transgenic animal | (1804) |
| 12 | Non - transgenic animal | |

Fig. 4


Figure 5

(A)



A

(B)



B

Figure 6

(A)



A

(B)

B

Figure 7

(A)


A

(B)

B

Figure 8

(A)



(B)




Figure 9

(A)



(B)



(19)



(11)

EP 0 653 154 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
04.12.1996 Bulletin 1996/49

(51) Int. Cl.⁶: **A01K 67/027**

(43) Date of publication A2:
17.05.1995 Bulletin 1995/20

(21) Application number: 94117512.7

(22) Date of filing: 07.11.1994

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE

(30) Priority: 12.11.1993 JP 306026/93

(71) Applicant: HOECHST JAPAN LIMITED
Tokyo 107 (JP)

(72) Inventors:

- **Sato, Masahiro**
Kawagoe-shi, Saitama 350-11 (JP)
- **Kobayashi, Takashi**
Fukuoka-shi, Fukuoka 812 (JP)

- Tada, Norihiro
Kawagoe-shi, Saitama 350-11 (JP)
- Shoji, Mikio
Gunma-cho, Gunma 370-35 (JP)
- Kawarabayashi, Takeshi
Maebashi-shi, Gunma 371 (JP)

(74) Representative: Bösl, Raphael Konrad, Dr. et al
Hoechst AG
Zentrale Patentabteilung
Gebäude F 821
65926 Frankfurt am Main (DE)

(54) Transgenic animal for alzheimer's disease

(57) This invention relates in general to an animal model that is useful for developing therapeutic drugs of a disease. More in detail, the present invention relates to the creation of transgenic animals having an exogenous gene construct coding a part of β -amyloid precursor protein (hereinafter called APP) in their genome. The exogenous gene construct is designed to overexpress in various types of the cells.




Fig 1

EP 0 653 154 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 11 7512

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|--|--|--|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int.Cl.4) |
| P,X | EXP.NEURL., vol. 127, no. 2, February 1994, pages 253-264, XP002014617 FUKUCHI, K.-I. ET AL.: "Overexpression of a C-terminal portion of the A-amyloid precursor protein in mouse brains by transplantation of transformed neuronal cells" * the whole document * | 1-10 | A01K67/027 |
| X | WO-A-93 14200 (TSI CORPORATION) 22 July 1993 | 1-6,8-10 | |
| Y | * page 8, line 7 - page 10, line 19 * * page 14, line 24 - page 16, line 37 * * page 20, line 10 - page 26, line 15 * | 7 | |
| X | WO-A-91 19810 (CALIFORNIA BIOTECHNOLOGY INC.) 26 December 1991 | 1,2,6, 8-10 | |
| Y | * page 10, line 1 - page 11, line 19 * * page 15, line 15 - line 25 * * page 21, line 10 - page 23, line 2 * * page 24, line 18 - page 27, line 3 * * page 28, line 33 - page 33, line 11 * * page 64, line 1 - page 66, line 11; figure 2; examples 4,6,8 * | 3-5,7 | TECHNICAL FIELDS SEARCHED (Int.Cl.4) |
| | | | A01K |
| X | J.BIOL.CHEM, vol. 266, no. 32, November 1991, pages 21331-21334, XP002014618 SANDHU, F.A. ET AL.: "Expression of the human A-amyloid protein of Alzheimer's Disease specifically in the brains of transgenic mice" | 1,2,6, 8-10 | |
| Y | * the whole document * | 3-5,7 | |
| | | -/-- | |
| The present search report has been drawn up for all claims | | | |
| Place of search MUNICH | | Date of completion of the search 27 September 1996 | Examiner Donath, C |
| CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons Δ : member of the same patent family, corresponding document | |

EPO FORM 1503 (01.92) (P04C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 11 7512

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|---|--|---|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int.Cl.6) |
| Y | BIOCHEM.BIOPHYS.RES.COMMUN., vol. 182, no. 1, January 1992, pages 165-173, XP002014619 FUKUCHI, K.-I. ET AL.: "Overexpression of amyloid precursor protein alters its normal processing and is associated with neurotoxicity" * the whole document * | 2-5,7 | |
| Y | SCIENCE, vol. 259, January 1993, pages 514-516, XP002014620 CAI, X.-D. ET AL.: "Release of excess amyloid A protein from a mutant amyloid A protein precursor" * the whole document * | 2 | |
| T | AM.J.PATHOL., vol. 149, no. 1, July 1996, pages 219-227, XP002014621 FUKUCHI, K.-I. ET AL.: "High levels of circulating A-amyloid peptide do not cause cerebral A-amyloidosis in transgenic mice" * the whole document * | 1-10 | |
| The present search report has been drawn up for all claims | | | TECHNICAL FIELDS SEARCHED (Int.Cl.6) |
| Place of search MUNICH | | Date of completion of the search 27 September 1996 | Examiner Donath, C |
| <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>⌘ : member of the same patent family, corresponding document</p> | | | |

EPO FORM 1501 (01.92) (P04C01)